Recormon 5000

• Anaemia of Chronic Renal Failure: Treatment of anemia in CKD patients.
• Anaemia in Zidovudine-treated HIV-infected Patients: Prevention and treatment of anemia in HIV patients.
• Anemia Related to Non-Myeloid Malignant Disease Chemotherapy: Treatment of anemia in cancer patients receiving chemotherapy.
• To Reduce the Need for Allogenic Blood Transfusion: Reduce transfusion requirements before surgery.
• Anaemia of Prematurity: Treatment of anemia in premature infants.

Adult Dose (Chronic Renal Failure):

• On dialysis (not on ESA therapy): 0.6 mcg/kg IV/SC q2week initially; initiate when Hb <10 g/dL.
• Currently receiving other ESA (epoetin <8000 units/week): 120 mcg/month or 60 mcg/q2week IV/SC
• Epoetin 8000-16000 units/week: 200 mcg/month or 100 mcg/q2week IV/SC
• Epoetin >16000 units/week: 360 mcg/month or 180 mcg/q2week IV/SC

Child Dose: Safety and efficacy not established.

Common Side Effects (>10%):

• Hypertension (13%)
• Diarrhea (11%)
• Nasopharyngitis (11%)

Occasional Side Effects (1-10%):

• Headache (9%)
• Upper respiratory tract infection (9%)
• Cough (6%)
• Hypotension (5%)
• Urinary tract infection (5%)
• Arteriovenous fistula thrombosis (5%)

Rare Side Effects: Coronary artery disease, septic shock, serious cardiovascular and thromboembolic events, seizures, PRCA, Stevens-Johnson syndrome, toxic epidermal necrolysis.

Precautions:

• Caution in hypertension, history of seizure, thrombocytosis, chronic hepatic impairment, ischaemic vascular disease, malignant tumours, epilepsy; recent MI or CVA.
• Iron deficiency, infection, inflammatory disorders, haemolysis and aluminium intoxication may decrease response.
• Regularly monitor platelet counts and serum-potassium concentrations.
• Control haematocrit levels.
• Poorly-controlled hypertension: Monitor BP, Hb and electrolytes.
• Anemia (eg, megaloblastic or folic acid): Give Fe supplements when needed.
• Thrombocytosis: monitor platelet count for 1st 8 weeks.